High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
暂无分享,去创建一个
A. López-Guillermo | J. Sierra | J. Rodríguez | J. S. San Miguel | A. Sureda | R. Arranz | A. Gutiérrez | M. Caballero | E. Conde | E. Carreras | A. F. de Sevilla | J. Zuazu | A. León | M. Gandarillas | J. C. Olivo Marin | José Rodríguez
[1] A. F. Sevilla,et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] P. Gaulard,et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] F. Cabanillas,et al. Outcomes Using Doxorubicin-Based Chemotherapy with or without Radiotherapy for Early-Stage Peripheral T-cell Lymphomas , 2002, Leukemia & lymphoma.
[4] A. Zelenetz,et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. , 2000, Blood.
[5] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] P. Gaulard,et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.
[7] A. Melnyk,et al. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. , 1997, Blood.
[8] James Olen Armitage,et al. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.
[9] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[10] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[11] P. Mclaughlin,et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] R. Warnke,et al. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] F. Berger,et al. Original article: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen , 1990 .
[14] F. Berger,et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] D. Weisenburger,et al. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Weisenburger,et al. Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation. , 1989, The American journal of medicine.
[17] Y. C. Chen,et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades--should peripheral T-cell lymphoma be considered separately? , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[19] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .